RPESC-RPE
Cell therapyexperimental
Clinical trial activity
1 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2021 (NCT04627428)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- RetinaTissue restoration
tissue restoration - retina
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04627428 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2021 | Luxa Biotechnology, LLC, National Eye Institute (NEI), National Institutes of Health (NIH), Regenerative Research Foundation, University of Michigan |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Luxa Biotechnology, LLC | For profit | 1 | 1 | 1 | 2021 |
| National Eye Institute (NEI) | Government | 1 | 0 | 1 | 2021 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2021 |
| Regenerative Research Foundation | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Michigan | Academic/Hospital | 1 | 0 | 1 | 2021 |
5 organizations
Page 1 / 1